Method of treating chronic endometritis

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gynaecology, reflexotherapy and pelotherapy. A method includes carrying out a course of antibacterial and/or antiviral therapy, which is started on 5-7 day of a menstrual cycle. From 5-7 day of the following menstrual cycle a course of pharmacopuncture is performed by introduction of homeopathic preparations into acupuncture points (AP). On 1, 3, 5, 7, 9, 11 and 13 days of the course Traumel C is introduced into points E36 (2), V31 (2), V32 (2), V33 (2), V34 (2). On 2, 4, 6, 8, 10, 12, 14 days of the course Ovarium compositum is introduced in AP Rp6 (2). Simultaneously with the course of pharmacopuncture or starting from 5-7 day of the following menstrual cycle a course of pelotherapy is carried out. Introduction of gel, based on the Dead Sea mud, is performed rectally for 30 minutes, 1 time per day.

EFFECT: method ensures recovery of the two-phase menstrual cycle due to normalisation of endometrium and vagina biocenosis, improvement of local immune and vegetative status, increases duration of remission.

4 cl, 2 ex

 

The invention relates to medicine, namely to gynecology, acupuncture and pelotherapy, and can be used for the treatment of chronic endometritis (CE), including women with miscarriage.

The frequency of chronic endometritis varies widely from 0.2 to 67%, averaging 14%. In recent years there has been a tendency to increase the frequency of chronic endometritis, which may be connected with the wide use of intrauterine contraceptive devices, the increase in the number of abortions and various intrauterine manipulation, including endoscopic methods. The presence of chronic endometritis (CE) is often the cause of reproductive disorders. At 88,2% of women with chronic endometritis develops in the reproductive age and leads to disruption of the menstrual, secretory and generative functions. Despite existing schema therapy of this pathology, there is a high percentage of reproductive disorders. In 59.9% of women with unsuccessful attempts at IVF and embryo transfer in history diagnosed with HAE. Among women with HAE in 60,4% of cases are diagnosed infertility: 24.8% primary, 35.6% secondary (49). More than 70% of women with HAE have a history of habitual miscarriage. In this regard, the improvement of existing and development of new methodology is the treatment of chronic endometritis remains an urgent task.

Treatment of chronic endometritis includes the first stage of antibacterial therapy taking into account the sensitivity; the second stage involves the use of vasotropic preparations for the normalization of the microcirculation, drugs to improve receptively endometrium, desensibiliziruyuschey therapy and immune disorders. The primary method of treatment in the second stage is physiotherapy with many recommended methods: ultrasound in pulsed mode, diadynamic currents, electrophores with iodine Kalia, zinc, lidsay, currents supersonic frequency (Strugatsky V.M. Physical factors in obstetrics and gynecology. - M, Medicine, 1981).

However, these methods have the following disadvantages: lack of efficacy, duration of recovery processes in the endometrium, a large number of relapses, the dampening effect of potassium iodide on the processes of follicle Genesis.

There is a method of treatment of chronic endometritis, including the introduction of the patient intramuscularly 1 ml of 1% solution of nicotinic acid and the impact of skin on the lower abdomen of low-intensity infrared laser radiation with a wavelength of 0.89 μm, a frequency of 600 Hz, a peak power of 5 watts, for 8-10 minutes, daily, course of 10-12 treatments (RU # 2233186, C1, 27.07.2004).

The disadvantages of this method of treatment is the low efficiency of treatment, in addition, some of what's patients is intolerance and allergic reaction to nicotinic acid.

There is a method of treatment of chronic endometritis by introducing into the vagina gel based on Dead sea mud. The gel based on Dead sea mud is available in disposable injectors with disposable vaginal/rectal catheters. In one injector contains up to 60 ml of gel based on Dead sea mud. In supine lying, the catheter is inserted into the vagina to 8-10 cm and dirt is squeezed out of the injector. The duration of the procedure - 20-25 minutes Then the dirt is removed from the vagina douching boiled water at a temperature of 35-36°C. the Procedures carried out daily or every other day. The treatment course of 6-12 treatments. (http://www.bilifemed.com/_mgxroot/page_10695.html viewed July 02, 2012).

However, this method of treatment is not effective enough. Less than 60% of patients have effect from treatment, more than 50% of these patients, i.e. patients who received the effect of treatment, returned with the same complaint within two years. So, out of 38 patients treated in this way, the disappearance of clinical complaints after treatment was noted on 22 patients, remission for more than 2 years was observed in 10 patients. In addition, vaginal introduction of dirt is not very comfortable for patients.

There is a method of treatment of chronic endometritis, including the use of extract of medicinal plants and hirudotherapy, which start with a 5 day herbal medicine ku is the com of 16 sessions, while leeches put in the umbilical region, on the edge of the right costal arch, xiphoid process, coccyx, inside the vagina, the perineum, the lateral arches of the vagina, on the reflex points of C3, Th4, VC-2, BG-4, VB-29, VG-20, E-36, RP-6, VC-3, R-18, V-31, F-11, VC-4, VC-7, R-5, F-27, E-29, VC-1 (EN No. 2192268, C1, 10.11.2002).

However, this method of treatment is not effective enough. In addition, the use of leeches is not very comfortable for some patients.

The purpose of the invention is the improvement of treatment effectiveness, enhancing the comfort of the treatment.

This objective is achieved in that on the 5-7th day of the menstrual cycle begin a course of antibacterial and/or antiviral therapy. After completion of the course of drug therapy, for 5-7 day of the next menstrual cycle begins the course of pharmacopuncture, which includes the introduction of homeopathic medication Traumeel C in acupuncture points (AT) E36 (2), V31 (2), V32 (2), V33 (2), V34 (2) in 1, 3, 5, 7, 9, 11 and day 13 of treatment and Ovarium of compositum at Rp6 (2) in 2, 4, 6, 8, 10, 12, 14 day treatment. Each injected AT 0.2-0.5 ml of the drug. After a course of pharmacopuncture at the same time or carry out a course of mud, including the introduction of rectal 60 ml of gel based on Dead sea mud. The gel is injected in the evening, 30 minutes, 1 time a day, every day. The course of treatment is 10-12 procedures.

Comparative analysis of the prototype showed that the proposed method cured the I is different from the known which further affect AT V32, V33, V34, while at the beginning of the treatment course of antibacterial and/or antiviral therapy, which start at 5-7 day of the menstrual cycle; then starting with 5-7 day of the next menstrual cycle are pharmacopuncture homeopathic medicines, 1, 3, 5, 7, 9, 11 and 13 days carry out the drug Traumeel C AT E36 (2), V31 (2), V32 (2), V33 (2), V34 (2), and in 2, 4, 6, 8, 10, 12, 14 day - drug Ovarium of compositum at Rp6 (2). Each injected AT 0.2-0.5 ml homeopathic remedy. In addition, simultaneously with pharmacopuncture or starting with 5-7 day of the next menstrual cycle, undergo treatment using gel based on Dead sea mud, which is administered rectally for 30 minutes 1 time a day, at night, through the day. The course of treatment is 10-12 procedures.

Thus, the proposed solution meets the criteria of the invention of "novelty."

The analysis of patent literature showed that the proposed method differs not only from the prototype, but also from other solutions in this and related fields. So, the authors have not found a method of treatment, which would include the proposed modes, namely, the proposed scheme of treatment to relieve pain, eliminate discomfort in the vagina, to restore reprodu the tive function, to normalize the microbiocenosis of the endometrium and vagina, to improve the local immune status and vegetative status, to prolong the period of remission. The proposed method of treatment is well tolerated by rectal injection of an injector with a gel based on Dead sea mud is more convenient compared with intravaginal, does not require after washing out mud, dirt is removed with the act of defecation. In addition, this method of administration allows for a more rapid and complete" the absorption of active substances from the dirt. Thus, the proposed method has high efficiency and comfortable for patients.

This method can be used in clinics, hospitals, sanatoriums in the treatment of HAE.

Thus, the proposed solution meets the criteria of the invention "inventive step" and "industrial applicability".

The method is as follows: for 5-7 day of the menstrual cycle begin a course of drug therapy taking into account the susceptibility of the identified pathogen, which aims to eliminate the infection (antibiotic therapy, antiviral therapy).

After completion of the course of drug therapy, for 5-7 day of the next menstrual cycle begin a course of treatment, which includes the introduction of homeopathic medication Traumeel C and Ovarium-compositum at at. The Traum is ü C enter in point E36 (2), V31 (2), V32 (2), V33 (2), V34 (2) in 1, 3, 5, 7, 9, 11 and 13 day course of treatment (7 procedures), and Ovarium compositum give points Rp6 (2) in 2, 4, 6, 8, 10, 12, 14 day treatment (7 procedures). The procedure is performed in the supine position. Injections are performed using an insulin syringe, inject 0.2-0.5 ml of the drug in each AT. The depth of introduction of the canonical up to the sensations provided (spreading, the passage of current, burning). Duration of treatment is 14 procedures.

Used drugs firm "Biologiche Heilmittel heel GmbH (Baden-Baden, Germany). All of the drugs approved for use in the Russian Federation in the form of subcutaneous, intradermal and intramuscular injections. Registration certificate of drugs: Ovarium compositum No. 05840/01 from 13.07.2004, Traumeel C No. 011686/04 dated 12.05.2006,

After a course of pharmacopuncture at the same time or carry out a course of treatment using Dead sea mud. Injector containing 60 ml of gel based on Dead sea mud, administered rectally in the evening, 30 minutes, 1 time a day. Of the procedures performed in a day. The course of treatment is 10-12 procedures. If the mud is carried out after completion of the course of pharmacopuncture, the rate of mud start at 5-7 day of the next menstrual cycle.

Registration certificate of the gel based on Dead sea mud No. SDF 2007/00358, Russia.

Example 1. Patient D., 35 Le is.

He complained of recurrent miscarriage (frozen pregnancy in the period of 8-9 weeks), perimenstrually scant spotting for 2 years, periodically pains and burning in the lower abdomen, pain during bimanual examinations.

Previously (within 2 years) received standard therapy (anti-inflammatory, hormonal therapy, physiotherapy), received a Spa treatment. The treatment effect is not given.

MRI performed on day 22 of the menstrual cycle, - M-the echo 8 mm with single hyperechoic inclusions in the basal layer and a slight decrease in blood flow. Tests of functional diagnostics revealed anovulatory cycles.

The result of histological examination of the endometrium: 6th DMZ. - dense stroma with diffuse fibrosis; irregular, diffuse lymphoid infiltration - signs of chronic endometritis.

Hormonal background: there has been decline in progesterone - 1.6 nmol/l (norm 10-89 nmol/l).

Screening for urogenital infection - negative result.

A survey of endometrial conditionally pathogenic microflora with definition of sensitivity to antibiotics. Were isolated: Staphylococcus epidermal >104CFU/ml with high hemolytic activity; Enterococcus faecalis >106CFU/m

Diagnosis: Chronic nonspecific shall endometric. Secondary ovarian dysfunction in type hypoprolactinemia. The miscarriage.

The treatment by the proposed method: starting from 5th day of the menstrual cycle was performed antibacterial therapy, including acceptance of ciprofloxacin 500 mg 2 times a day for 10 days, tinidazole 500 mg 4 tab. a day for 2 days.

Starting from 5th day of the next menstrual cycle spent course of treatment, which included the introduction of homeopathic medication Traumeel C and Ovarium compositum at at. Homeopathic drugs were injected every other day, alternating drugs. The Traumeel C was introduced in point E36 (2), V31 (2), V32 (2), V33 (2), V34 (2) in 1, 3, 5, 7, 9, 11 and 13 day course of treatment (7 procedures), and Ovarium compositum was introduced in point Rp6 (2) in 2, 4, 6, 8, 10, 12, 14 day treatment (7 procedures). The procedure was performed in the supine position. Injection was performed using an insulin syringe, injected 0.2 ml of the drug in each AT. The depth of introduction of the canonical up to the sensations provided (spreading, the passage of current, burning). The duration of treatment was 14 procedures.

After a course of pharmacopuncture, starting from 5th day of the next menstrual cycle, carried out the course of treatment using gel based on Dead sea mud. 60 ml of gel was administered rectally, in the evening, 30 minutes, 1 time a day, every day. The course of treatment - 10 sessions.

Control is the first inspection one month after the end of treatment: patient noted the disappearance of perimenstrually light discharge the absence of pain and burning in the lower abdomen. In the second cycle assessed the level of progesterone level was 54 nmol/l, which indicates the normalization level of progesterone in the blood. Planned control study of the endometrium, but the woman was delay menstrual period and ultrasound diagnosed with uterine pregnancy, which ended in childbirth term healthy full-term child. The patient was under observation for 3 years after the child's birth. Complaints were not filed, menstruation recovered a year later, the lactation period was 10 months.

Example 2. Patient U., 26 years.

Complaints about the miscarriage (frozen pregnancy in the period of 6 weeks), intermenstrual scant spotting for 2 cycles, dysmenorrhea during 6 cycles, lower abdominal pain, discomfort in the vagina. Associated diseases - chronic superficial gastritis. Previously held medical therapy and physiotherapy. The treatment effect is not given.

Screening for urogenital infections revealed a ureaplasmosis >104CFU/ml, mycoplasmosis >104CFU/ml by the method of bacteriological seeding, PCR diagnosis of HSV and CMV infection gave negative results by ELISA diagnosis of these viruses revealed the presence of Ig M 1:40 to HSV and Ig G 1:3200 to HSV.

Hormones: the tendency to snijeniyu progesterone 20 nmol/l (norm 10-89).

Ultrasound diagnosis: M-echo 7 mm (22 DMZ.), single hyperechoic inclusions in the basal layer with reduced blood flow.

Results histological examination of the endometrium: the endometrium phase of proliferation foci of lymphoplasmacytic infiltration with isolated neutrophils and eosinophils, periglandular and perivascular, focal fibrosis is a picture of chronic endometritis. Tests of functional diagnostics revealed ovulatory cycles with luteal phase deficiency.

The diagnosis of Chronic endometritis. Ureaplasmosis. Mycoplasmosis. Herpes infection, stonetree. The miscarriage.

The treatment by the proposed method: starting from the 7th day of the menstrual cycle was performed antibacterial and antiviral therapy including receiving at the first stage: Unidocs of Solutab 100 mg - 2 tablets. 1 day and 1 tablet. in the next 8 days, tinidazole 500 mg 4 tab. a day for 2 days, valtrex 500 mg 1 tab. 2 times a day for 10 days.

On the 7th day of the next menstrual cycle began a course of treatment, which included the introduction of homeopathic medication Traumeel C and Ovarium compositum in AT and mud by using a gel based on Dead sea mud.

Preparation Traumeel C was introduced in point E36 (2), V31 (2), V32 (2), V33 (2), V34 (2) in 1, 3, 5, 7, 9, 11 and 13 day course of treatment (7 procedures), and Ovarium compositum waters is whether in point Rp6 (2) in 2, 4, 6, 8, 10, 12, 14 day treatment (7 procedures). Procedures were performed in the supine position. Injections were performed using an insulin syringe was injected at 0.5 ml each AT. The depth of introduction of the canonical up to the sensations provided (spreading, the passage of current, burning). Duration of pharmacopuncture - 14 procedures.

Simultaneously with the course of pharmacopuncture the patient carried out the course of mud. 60 ml of gel based on Dead sea mud was administered rectally, in the evening, 30 minutes, 1 time a day every other day. The course of treatment is 12 procedures.

One month after the end of treatment control examination showed the disappearance of intermenstrual bleeding, absence of painful menstruation, progesterone level was 73 nmol/l; ultrasound study - M-echo 23 DMZ. was 8 mm, with a mean flow. After 2 cycle came tubal pregnancy, which is currently being hatched.

All of the proposed method was treated 64 women with HAE. All women after treatment was noted:

- the disappearance of pain in the lower abdomen and lumbar region;

- normalization of function of the gastrointestinal tract and the urinary system;

- the disappearance of burning sensation in the lower abdomen;

- recovery of secretory and menstrual function, the appearance of the 2 phase of the menstrual cycle;

- the reduction or disappearance of the disk is ORT, dryness and itching in the vagina;

- the reduction of pain during bimanual examinations;

- restore 2 Stoichita vaginal secretions;

- according to the results of Doppler studies normalization or improvement of microcirculation basal layer to the second phase of the menstrual cycle;

- marked increase in M-echo of patients with gipoplasticheskaya option HAE.

The control patients was carried out over 3 years. For three years 62 treated by the proposed method patients has not filed any complaints, 2 women were treated with the same complaints. During this period of observation in 42 patients (65, 6%) came pregnancies in spontaneous cycle and currently 36 pregnancies ended with the birth of a healthy full-term newborns, 6 - incubating.

Thus, the proposed method can improve the effectiveness of treatment of chronic endometritis, while the proposed method is well tolerated and comfortable for patients.

1. The method of treatment of chronic endometritis, including the effect on the acupuncture points (AT) V31, E36, Rp6 and medications, characterized in that it further affect AT V32, V33, V34, while at the beginning of the treatment course of antibacterial and/or antiviral therapy, which start at 5-7 day of the menstrual cycle; then, starting the 5-7 day of the next menstrual cycle, spend pharmacopuncture homeopathic medicines, 1, 3, 5, 7, 9, 11 and 13 days carry the drug With Traumeel in AT E36 (2), V31 (2), V32 (2), V33 (2), V34 (2), and in 2, 4, 6, 8, 10, 12, 14 day - drug Ovarium of compositum at Rp6 (2); in addition, simultaneously with the course of pharmacopuncture or starting with 5-7 day of the next menstrual cycle, undergo mud involving the introduction of a rectal gel based on Dead sea mud for 30 minutes, 1 time a day.

2. The method according to claim 1, characterized in that each injected AT 0.2-0.5 ml homeopathic remedy.

3. The method according to claim 1, characterized in that the injected 60 ml of gel based on Dead sea mud.

4. The method according to claim 1, characterized in that the course of treatment consists of 10-12 procedures.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the chemical-pharmaceutical industry and deals with application of fullerene derivatives of the general formula 1

,

where in the general formula 1 fragment C2n stands for: fullerene carbon cage C60 (n=30), C70 (n=35); where in the general formula 1 "x" can take values from 4 to 12, and "y" from 0 to 16, where in the general formula 1 fragment A stands for a monovalent atom of fluorine or hydrogen; -oxygen atom (-O-), bound to the fullerene cage in a composition of an oxirane fragment; where in the general formula 1 NR1R2 is described by the following definitions: - amine residue, where R1 and R2 are hydrogen atoms or substituted with protonated (NH3+) or unprotonated (NH2) aminogroups or branched alkyl radicals (CmH2m+1; m=1-20); - residue of piperazine of the general formula Ic-1 , where R, R'1, R'2 R'3 and R'4 are hydrogen atoms or linear or branched alkyl (CmH2m+1 m=1-20) radicals, as antimicrobial preparations, as well as an antimicrobial composition, including fullerene derivatives.

EFFECT: invention can be used in biomedical research and in production of novel medications, intended for treatment and prevention of infectious diseases, as well as for creation of disinfection agents, intended for decontamination and sterilisation of media and surfaces contaminated with microorganisms.

2 cl, 4 ex, 2 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using a compound of formula (1) or its salt for preparing a drug for increasing HIF-1α stabilisation in a cell, as well as for preparing a drug enhancing the immune response in an individual, for preventive management of a wound to avoid an infection, for treatment of the microbial infection, for improvement of efficacy of a vaccine for management of the wound in the individual. What is presented is a pharmaceutical composition containing the above HIF-1α prolyl hydroxylase inhibitor and one or more additives. What is shown is achieving the declared applications by using the new compound of formula (1) with the HIF-1α prolyl hydroxylase (HIFPH2 (EGLN1)) inhibitor. It makes it applicable for treating HIF-1 alpha activity related diseases, conditions and/or syndromes.

EFFECT: preparing the drug for increasing HIF-1α stabilisation in a cell.

26 cl, 20 dwg, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: method for prevention of ixodic tick-borne borreliosis in children by an antibacterial therapy consists in the fact that after establishing the fact of Borrelia infected tick suction, ceftriaxone 50 mg/kg a day is injected intramuscularly for 3 days in a combination with a single intramuscular injection of bicillin 5 in a dose of 50 thousand IU/kg; anaferone is also prescribed in a dose of 1 tablet 3 times a day for 30 days.

EFFECT: method provides efficacy and safety that promotes reducing the incidence of ixodic borreliosis.

1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to antibacterial compounds of formula (I), where R1 represents alkoxygroup; U, V and W each represents CH or one of U, V and W represents N, and each other represents CH; A represents CH2 or O; G represents CH=CH-E, where E represents phenyl group, mono- or di-substituted with halogen, or G represents group of one of the formulas given below , , where Z represents CH or N, Q represents O or S and K represents O or S; or salt of such compound. In addition, invention also relates to pharmaceutical composition based on formula (I) compound for prevention or treatment of bacterial infection, as well as to application of claimed compounds for obtaining medication for prevention or treatment of bacterial infection.

EFFECT: novel compounds, which can be applied in treatment of bacterial infection, are obtained and described.

23 cl, 1 tbl, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science and medicine, and may be used to prevent and treat bacterial infections. An antibacterial injectable pharmaceutical composition comprises azithromycin, solvents and/or co-solvents, a preserving agent, and an antioxidant. The antioxidant is presented by ascorbic acid, or sodium ascorbate, or calcium ascorbate, or palmityl ascorbate, or 4-methyl-2,6-ditertbutylphenol, or tertbutylhydroquinone, 2,4,5-trihydroxybutyrophenone, or sodium metabisulphite, or alpha tocopherol, or thioglycerol, or combinations thereof; the preserving agent is presented in the form of benzyl alcohol, parabenes, chloroethanol or combinations thereof; the solvents or co-solvents are organic solvents, including dimethylacetamide, or dimethylsulphoxide, or N-methyl-2-pyrrolidone, or 2-pyrrolidone, or combinations thereof, or combinations of organic solvents with water in the following relations, wt %: azithromycin 5-50, antioxidant 0.1-0.2, preserving agent 1-2, pH regulator up to 5, solvents the rest.

EFFECT: antibacterial injectable pharmaceutical composition of azithromycin possesses a wide spectrum of the antimicrobial action, and is applicable to the intravenous, intramuscular, subcutaneous, intrauterine and intracisternal introduction.

3 cl, 1 dwg, 7 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biochemistry and discloses a polypeptide having antimicrobial activity, which includes an amino acid sequence having at least 70% identity with an amino acid sequence corresponding to positions 1-21 of SEQ ID NO:2. The invention also relates to structures of nucleic acids, vectors and host cells which include a polynucleotide which encodes the polypeptide according to the invention, as well as a method of producing such a polypeptide and use of the polypeptide to destroy microbe cells.

EFFECT: invention widens the range of antimicrobial polypeptides.

18 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to macrolide derivative, namely to hydrate of erythromycin salts, which has molecular formula C37H67NO13·A·nH2O, n=1, 5; 2; 3; 3.5; 5; 6 or 11, where A represents lactobionic acid or thiocyanic acid, with n=3; 3.5; 5; 6 or 11, if A is lactobionic acid and n=1.5; 2 or 3, if A represents thiocyanic acid. Hydrate possesses good water solubility and better stability in storage, which is convenient for production of medication for treatment and prevention in people and animals of infectious diseases caused by bacteria, mycoplasms or chlamydia, sensitive to erythromycin. Also claimed is method of obtaining hydrate of erythromycin salts and its application for preparation or purification of erythromycin.

EFFECT: obtaining pharmaceutical composition, possessing antibacterial activity.

14 cl, 20 ex, 12 tbl, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and veterinary science. A method provides using bacterial 7P ribonuclease for increasing the effectiveness of suppression of RNA- and DNA-containing virus replication for treating acute viral diseases in mammals and warm-blooded animals.

EFFECT: Bacillus intermedius RNAase suppression of virus replication is ensured by using substantially lower doses of enzymes introduced into an infected body with the increased effectiveness of virus replication and therapeutic process.

2 cl, 8 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science, namely to obstetrics and gynaecology. A preparation for treating and preventing sub-clinical, clinical, acute and chronic mastitis in farm and domestic animals contains an active substance that is - triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide and a pharmaceutically acceptable carrier that is Vaseline in ratio 1:2000.

EFFECT: invention provides the higher antimicrobial effectiveness and the lower toxicity of the ointment with the lower concentration of the active substance.

3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating mastitis in cows. The declared agent contains veterinary Vivaton - 10%, ASD-2 - 4%, Bursanatal - 6% and 0.9% normal saline up to 100%. The method involves administering the declared agent with underlying general strengthening and stimulating therapy. The agent is intra-cisternal into an involved one-quarter of a dug in a dose of 5 ml daily once a day using a syringe in number of 3-5 procedures.

EFFECT: using the declared group of invention enables providing higher efficacy in treating mastitis in cows.

2 cl, 7 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of veterinary and is intended for activation of reproductive function in Karakul sheep. A biological preparation, including a female placenta extract and vitamins, is characterised by the fact that it additionally contains phytoextracts (in which a physiological solution is used as an extractant) of seeds of desert forage plants - annual Salsola: Salsola sclerantha C.A.M, Gamanthus gamocarpus Mog, Climacoptera lanata Pall., and phytoextracts (in which the physiological solution is used as the extractant): of rhizomes of Sweet flag (Acorus calamus L.) and caper (Capparis spinosa L.) in a ratio placenta extract: phytoextracts as 1:2 and a water-soluble vitamin-amino acid complex "Chiktonic", with the following component ratio, ml: an extract of female placenta 100, a phytoextract of seeds of Salsola sclerantha C.A.M. 30, a phytoextract of seeds of GamanthusgamocarpusMog 40, a phytoextract of seeds of Climacoptera lanata Pall. 40, a phytoextract of rhizomes of Sweet flag (Acorus calamus L.) 40, a phytoextract of seeds of caper (Capparis spinosa L.) 50, the water-soluble vitamin-amino acid complex "Chiktonic" 2.

EFFECT: application of the claimed preparation contributes to activation and normalisation of reproductive function in sheep, increases synchronicity of passing ewes in the state of readiness and fertility.

3 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intracisternal administration of masticef at a dose of 5 ml with 24-hour intervals 2-4 times. The biogenic stimulator is used as a preparation obtained from pig spleen (BSS) by ultrasonic homogenisation, heating the homogenate, and its cooling, supernatant precipitation followed by removal of ballast proteins by centrifugation or ultrafiltration. The biogenic stimulator is administered subcutaneously in the upper third part of the neck in 1-3-5-7 days of treatment at a dose of 30-35-40-45 ml, respectively.

EFFECT: method enables to increase the effectiveness of treatment of all forms of mastitis in cows, to the reduce treatment time, and to reduce the term of milk rejection.

4 tbl, 3 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: biologically active composition for improving sexual function in men includes powder of antlers of Maral, or Manchurian wapiti, or sika deer, and additionally contains powder of leaves or rhizomes with roots of Rhaponticum carthamoides, taken in specified ratio (version).

EFFECT: composition makes it possible to extend spectrum of highly efficient preparations for improvement of sexual function in men with minimal quantitative content of highly effective components from plant and animal raw material, demonstrating action synergism as components of composition.

4 cl, 6 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: against the background of lymphotropic injections of enzaprost F (prostaglandin F) and antibiotic in half-daily doses a course of lymph-stimulating injections is carried out in the subcutaneous tissue in the projection of the inguinal rings, which is administration into the interspinous ligament thickness of the spine at the level of L2-L6 of 1 ml per 5 kg of animal weight of mixture consisting of 32 IU lydase, 500 thousand IU roncoleukin, 0.1 ml butomidore, 4 ml of 2% lidocaine solution, and 5 ml of 40% glucose solution.

EFFECT: method enables to increase the effectiveness of therapy while reducing the probability of development of side effects and relapses of disease by increasing the drainage function of the lymphatic system, acceleration of lymph flow and processes of neogenesis while reducing the duration of treatment and reduction of daily doses.

1 tbl

FIELD: medicine.

SUBSTANCE: blood is examined for angiogenic factors, namely soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF). An angiogenic factor (Ka) is calculated by formula: Ka=sFlt-1/PlGF×10. If Ka is 10 or less, the pregnant woman is stated to require no admission to hospital, no case follow-up; doctor's appointments are scheduled. If Ka falls within the range of 10 to 50, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed; an amniotic fluid index (AFI) is calculated; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 10 days. The amount of infusion makes 400 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control ultrasonography, Doppler monitoring, foetal monitoring, AFI and Ka measurements are performed 2 weeks later. The pregnant woman is discharged from hospital if observing no negative trends. If Ka falls within the range of 50 to 100, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days The amount of infusion makes 800 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control Doppler monitoring and foetal monitoring are performed every 3 days; 2 weeks later control Ka is measured. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 100 or more, but less than 150, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days. The amount of infusion makes not less than 800 ml a day with the same preparations prescribed. Those are added with the preparations for homeostasis correction, including Fraxiparine, Fragmin, Clexane optionally. Control Doppler monitoring and foetal monitoring are daily. Hypamnion also requires measuring control AFI. If a gestational age is less than 34 weeks, respiratory distress syndrome (RDS) should be prevented by administering the preparation Dexon 24 mg according to the schedule: 6 mg every 12 hours 4 times. Control Ka is necessarily measured after 2 weeks of the treatment. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 150 or more, and the gestational age is more than 34 weeks, the therapeutic approach is the same, as for Ka being within 100 to 150, control Doppler monitoring, foetal monitoring are performed twice a day, as well as measuring AFI. If observing no foetal weight gain for 2 weeks of the therapy or the functional state of the foetus deteriorates, a Cesarean section is performed. If the gestational age is 34-36 weeks, the therapeutic approach and follow-up are the same as for the gestational age of 34 weeks, except for the prevention of foetal RDS. However, if observing the deterioration of a foetal movement pattern or the functional status of the foetus, a Cesarean section is performed according to the foetal monitoring and Doppler monitoring findings. If the gestational age is more than 36 weeks, and Ka is 150 or more, pre-mature delivery is applied.

EFFECT: optimal selection of the therapeutic approach ensured by determining the values reflecting the severity of the cardiovascular disorder directly in the uterine-placental complex and mother's and foetus's compensatory capacities.

5 ex

FIELD: veterinary medicine.

SUBSTANCE: suppositories comprise active substance triphenyl-(3,5-di-tret-butyl-4-hydroxybenzyl) phosphonium bromide in an amount of 1%. As the pharmaceutically acceptable carriers the suppositories comprise "polyethylene glycol-6000" (30%), higher fatty alcohols C16-C21 (0.6%), calcium stearate (0.8%) and sucrose (42.8%), foaming agents contain citric acid (10%), sodium bicarbonate (14.8%).

EFFECT: agent has high bactericidal, antimycotic, antioxidant activity, provides high curative and preventive effect for treatment and prevention of puerperal purulent-catarrhal endometritis in farm animals.

2 cl, 3 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: described are novel alkyl cyclohexyl esters of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives of formula I where R is C1-8-alkyl, optionally substituted with a halogen, hydroxy or C1-12-alkoxy, CF3, C3-7-cycloalkyl, a 4-6-member heterocycloalkyl containing one O, R is H, C1-8-alkyl, optionally substituted with OH, -(CH2)q-Ra, where Ra is a 6-member heteroaryl containing one N, -C(O)-C1-8-alkyl, where the alkyl is optionally substituted with OH, -C(O)(CH2)qOC(O)-C1-8-alkyl, -C(O)O-C1-8-alkyl, -S(O)2-C1-8-alkyl or -S(O)2NRiRii, where Ri and Rii are identical and denote C1-8-alkyl, q=1, R3 is Cl or F, and a pharmaceutical composition containing said compounds.

EFFECT: compounds are V1a receptor antagonists and can be used in medicine.

15 cl, 69 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, physiotherapy. A method involves the integrated treatment of the patients with genital endometriosis and hysteromyoma. The treatment involves taking mineral water, observing a biologically programmed light pattern, taking radon baths and radon gynaecological irrigations and small enemas, as well as conducting a laser therapy of biologically active points (BAPs). The patients take carbonated chloride-hydrocarbonate-sulphate sodium-calcium warm Narzan water taken from sources No. 4, No. 7 and No. 24, 3.4 mg per kg 3 times ad day, 40 minutes before meals. The radon baths are taken with the radon concentration of 1.5 kBq/l. The radon gynaecological irrigations and microenemas are performed with the radon concentration of 6.5 kBq/l, temperature 36°C, for 15 minutes within the course of 10-12 procedures. The BAP laser therapy is conducted in an autoresonant mode. The BAPs of anterior median meridian are covered, including: 1-2 (qu-gu), 1-3 (zhong-ji), 1-4 (guan-yuan), 1-5 (shi-men), 1-7 (yin-jiao); renal meridian: R-12 (da-ho), R-13 (qi-xu), R-14 (si-man), R-15 (zhong-zhu), R-16 (huang-shu); bladder meridian: V-31 (shang-liao), V-32 (ci-liao), V-33 (zhong-liao), V-34 (xia-liao); posterior median meridian: T-2 (yao-shu), T-3 (yao-yang-guan), T-4 (min-man), T-5 (xuan-shu). Using the radon baths of the different radon concentrations 'softens' an effect of the absorbed radiation dose on the homeostasis systems and preserves an effect of a high absorbed dose on the genital system. The laser therapy in the autoresonant mode within pathological BAPs improves the accuracy of the exposure on the pathological processes within a target organs.

EFFECT: method prolongs the remission, normalises the hormonal ratios in the remote period.

2 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: azithromycin infusions are combined with the daily administration of metronidazole. Azithromycin is administered in a single dose of 1.0 g on the 5th post-infusion day. The treatment is combined with the daily administration from the first day of the metronidazole therapy twice a day in a dose of 500 mg for 14 days.

EFFECT: effective treatment ensured by reducing a dose and risk of side effects.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, in particular to vascular surgery, and is intended for transfer of medications onto an internal surface of a vessel wall. A device for transfer of medications onto the internal surface of the vessel wall contains a matrix, made in the form of a polymer film, covered with medication and placed on a flexible framework. The matrix and the framework have specified standard sizes. They are made with a possibility of placement in them of a cellular knitted metal temporary stent and with a possibility to be inside the temporary stent of an inflatable balloon with a fixed diameter and length and a cylindrical or conic shape when blowing under high pressure or a latex balloon with a possibility of filling the entire internal space of the temporary stent when blowing under low pressure.

EFFECT: invention makes it possible to simultaneously perform long-term efficient transfer of medication into the vessel wall with preservation of blood flow and efficient diameter of the affected vessel.

4 cl, 1 dwg

Up!